A patent review of cyclin-dependent kinase 7 (CDK7) inhibitors (2018-2022)

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15310%2F23%3A73619591" target="_blank" >RIV/61989592:15310/23:73619591 - isvavai.cz</a>
Result on the web
<a href="https://www.tandfonline.com/doi/full/10.1080/13543776.2023.2195547" target="_blank" >https://www.tandfonline.com/doi/full/10.1080/13543776.2023.2195547</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1080/13543776.2023.2195547" target="_blank" >10.1080/13543776.2023.2195547</a>

Result language
angličtina
Original language name
A patent review of cyclin-dependent kinase 7 (CDK7) inhibitors (2018-2022)
Original language description
Cyclin-dependent kinase 7 (CDK7) is a member of the CDK family of serine/threonine protein kinases and participates in the regulation of the cell cycle and mRNA transcription. CDK7 is emerging as a possible drug target in oncology and six exciting drug candidates have already undergone early evaluation in clinical trials.
Czech name
—
Czech description
—

Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30107 - Medicinal chemistry

Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year
2023
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)